a) Intravenous Glycoprotein IIb/IIIa inhibitors are helpful, if the patient does not go to cath lab

Possibly

The binding of fibrinogen and von Willebrand's factor to the platelet glycoprotein IIb/IIIa receptor causes platelet clumping and is the final step in clot formation. The use of the IIb/IIIa inhibitors in preventing vessel closure after PTCA is well documented (11).

A recent comparison of patients not going to the catheterization lab of IIb/IIIa inhibitors (PURSUIT, PRISM, PRISM-PLUS, PARAGON A PARAGON B) showed a 1-3% absolute reduction in death and nonfatal MI at 30 days. Their conclusion was that patients with moderate to severe unstable angina should be started on this medication. Others researchers dispute the cost-benefit ratio. (12)

There may be more than one correct answer for this decision point.